Bicara Therapeutics (NASDAQ:BCAX) Stock Jumps 14.9% – What’s Next?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) rose 14.9% during trading on Monday. The stock traded as high as $9.75 and last traded at $9.9370. 898,956 shares traded hands during mid-day trading, an increase of 20% from the average daily volume of 748,023 shares. The stock had previously closed at $8.65.

Key Bicara Therapeutics News

Investors following BCAX have been watching these news items:

• Neutral Sentiment: Although HC Wainwright, Morgan Stanley, Stifel and BTIG each lowered their price targets, they maintained Buy or Overweight ratings. Their revised targets remain well above the recent share price, signaling continued analyst optimism alongside lower expectations. HC Wainwright recommendations Morgan Stanley recommendations
• Neutral Sentiment: A short-interest report listed zero shares sold short, so the supplied figures do not indicate meaningful short positioning; the entry’s description of a significant increase conflicts with that figure.
• Negative Sentiment: The four target cuts point to more cautious near-term assumptions: HC Wainwright lowered its target to $36 from $42, Morgan Stanley to $30 from $41, Stifel to $43 from $45, and BTIG to $37 from $39. The revisions could weigh on sentiment even though all retained bullish ratings.

Analysts Set New Price Targets

BCAX has been the topic of a number of research analyst reports. HSBC cut Bicara Therapeutics to an “equal weight” rating in a report on Tuesday, September 22nd. Wall Street Zen lowered Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 31st. BMO Capital Markets assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 price target on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Bicara Therapeutics in a research report on Tuesday. Finally, The Goldman Sachs Group cut shares of Bicara Therapeutics from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $20.00 to $8.00 in a report on Friday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.33.

Bicara Therapeutics Trading Up 3.4%

The company’s fifty day simple moving average is $17.63 and its 200 day simple moving average is $20.88. The stock has a market capitalization of $696.44 million, a P/E ratio of -3.04 and a beta of -0.33.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). Equities research analysts predict that Bicara Therapeutics Inc. will post -3.49 earnings per share for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the sale, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.80% of the company’s stock.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently bought and sold shares of the company. Sterling Capital Management LLC lifted its holdings in shares of Bicara Therapeutics by 457.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock worth $26,000 after acquiring an additional 1,138 shares during the last quarter. Profund Advisors LLC lifted its holdings in Bicara Therapeutics by 7.2% in the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock worth $314,000 after buying an additional 1,140 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Bicara Therapeutics by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock valued at $224,000 after purchasing an additional 1,617 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after buying an additional 2,447 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $63,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.